Looking specifically at the test results for the patients enrolled in the ToGA trial, the agreement between HER2 amplification and HER2 overexpression is somewhat lower in gastric cancer than typically observed in breast cancer (49, 50). This evidence concerns the gene ERBB2 and gastric cancer.